Company news
Neurogene Inc. (NASDAQ:NGNE) news
Neurogene Inc. news releases on 6ix. Latest, Oct 5, 2026: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 4, 2026
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
August 11, 2026
Neurogene Inc. Announces Pricing of $125 Million Public Offering
July 1, 2026
Neurogene Inc. Announces Proposed Public Offering
June 30, 2026
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
June 29, 2026
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
June 8, 2026
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
May 12, 2026
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
May 12, 2026
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 28, 2026
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
April 20, 2026
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
March 23, 2026
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
March 10, 2026
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
February 25, 2026
Neurogene to Participate in Upcoming Investor Conferences
February 5, 2026
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 4, 2026
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
January 12, 2026
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 4, 2025
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
November 13, 2025
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
November 12, 2025
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
November 6, 2025
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
October 9, 2025
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
October 8, 2025
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
August 11, 2025
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
June 30, 2025
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
May 16, 2025
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
May 9, 2025
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
April 28, 2025
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
April 2, 2025
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
March 24, 2025
Neurogene to Participate in Upcoming Conferences
February 24, 2025
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
November 17, 2024
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
November 17, 2024
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
November 10, 2024
Neurogene Announces Oversubscribed $200 Million Private Placement
November 3, 2024
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
October 20, 2024
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
August 8, 2024
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
August 6, 2024
Neurogene to Participate in BMO Genetic Medicines Summit
July 1, 2024
Neurogene Announces Addition to Russell 3000® Index
June 30, 2024
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
June 17, 2024
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
June 2, 2024
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
May 9, 2024
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
May 6, 2024
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
April 21, 2024
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
March 17, 2024
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
March 3, 2024
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
January 15, 2024